Mayo Clinic Develops Nanotherapy for Aggressive Brain Tumors
Researchers at the Mayo Clinic have developed an experimental nanotherapy aimed at treating glioblastoma, an aggressive form of brain cancer. This innovative approach involves using nanotechnology to deliver two cancer drugs directly to brain tumors, overcoming the challenge of the blood-brain barrier. The therapy combines everolimus or rapamycin and vinorelbine, packaged in lipid-based particles called liposomes, to target tumor cells effectively. In preclinical models, this method, when combined with radiation, significantly extended survival compared to untreated controls. The study, published in Communications Medicine, highlights the potential of this strategy to improve treatment outcomes for glioblastoma patients. 
